- Roche Canada completed pCPA negotiations for Perjeta (pertuzumab) with trastuzumab and chemotherapy as neoadjuvant treatment for HER2-positive, locally advanced, inflammatory or early breast cancer, bringing public access closer.
- The agreement, finalized August 10, follows CDA-AMC’s positive recommendation in October 2025 and negotiations launched in February 2026. Provincial and territorial drug plans will now determine public coverage.
- HER2-positive breast cancer accounts for 10–20% of Canadian cases and carries a high recurrence risk. Perjeta’s neoadjuvant use before surgery can reduce tumour size and help achieve a pathologic complete response.
- Roche says Perjeta in the neoadjuvant setting is an established global standard of care for high-risk HER2-positive early breast cancer and will work with jurisdictions to support timely public access across Canada.
Takeaways:
Roche Canada’s completion of pCPA negotiations for Perjeta (pertuzumab) in the neoadjuvant setting (with trastuzumab + chemotherapy) for HER2‑positive, locally advanced, inflammatory or early breast cancer removes a major pricing hurdle and moves the regimen closer to routine public funding once provinces/territories finalize coverage. 1000 Because this use is already a global standard of care for high‑risk early HER2‑positive disease and can increase pathologic complete response rates before surgery, broader Canadian access could shift more patients toward dual‑blockade neoadjuvant therapy, potentially improving surgical outcomes and long‑term recurrence risk.
Source: CA Newswire
